Join Growin Stock Community!

智擎4162.TW Overview

TW StockBiotech. & Medical
(No presentation for 4162)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

智擎(4162)Overall Performance

智擎(4162)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

智擎(4162) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

智擎(4162)Key Information

智擎(4162)Profile

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

智擎(4162)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
22.75
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
98.07%
Net Margin
66.86%
Revenue Growth (YoY)
201.11%
Profit Growth (YoY)
212.64%
3-Year Revenue Growth
16.06%
3-Year Profit Growth
17.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
22.75
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
98.07%
Net Margin
66.86%
Revenue Growth (YoY)
201.11%
Profit Growth (YoY)
212.64%
3-Year Revenue Growth
16.06%
3-Year Profit Growth
17.52%
default symbol

4162

智擎

62.80D

-2.07%

(-0.02)

  • When is 4162's latest earnings report released?

    The most recent financial report for 智擎 (4162) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4162's short-term business performance and financial health. For the latest updates on 4162's earnings releases, visit this page regularly.

  • Where does 4162 fall in the P/E River chart?

    According to historical valuation range analysis, 智擎 (4162)'s current price-to-earnings (P/E) ratio is 4.62, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 4162?

    According to the latest financial report, 智擎 (4162) reported an Operating Profit of 119.77M with an Operating Margin of 49.46% this period, representing a growth of 2.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4162's revenue growth?

    In the latest financial report, 智擎 (4162) announced revenue of 242.16M, with a Year-Over-Year growth rate of 10.97%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4162 have?

    At the end of the period, 智擎 (4162) held Total Cash and Cash Equivalents of 1.5B, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4162 go with three margins increasing?

    In the latest report, 智擎 (4162) achieved the “three margins increasing” benchmark, with a gross margin of 94.79%%, operating margin of 49.46%%, and net margin of 56.35%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4162's profit trajectory and future growth potential.

  • Is 4162's EPS continuing to grow?

    According to the past four quarterly reports, 智擎 (4162)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.95. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4162?

    智擎 (4162)'s Free Cash Flow (FCF) for the period is -5.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 222.36% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.